References
- Corne J M, Marshall C, Smith S, Schreiber J, Sanderson G, Holgate S T, Johnston S L. Frequency, severity, and duration of rhinovirus infections in asthmatics and non‐asthmatic individuals: a longitudinal cohort study. Lancet 2002; 359: 831–834, [PUBMED], [INFOTRIEVE]
- Gern J E, Vrtis R, Grindle K A, Swenson C, Busse W W. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med 2000; 162: 2226–2231, [PUBMED], [INFOTRIEVE], [CSA]
- Papadopoulos N G, Stanciu L A, Papi A, Holgate S T, Johnston S L. A defective type 1 response to rhinovirus in atopic asthma. Thorax 2002; 57: 328–332, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Papadopoulos N G, Bossios A, Syrigou E I, Gourgiotis D, Saxoni‐Papageorgiou P H. Interferon‐gamma pretreatment of peripheral blood mononuclear cells partially restores defective cytokine production in children with atopic dermatitis. Pediatr Allergy Immunol 1998; 9: 125–129, [PUBMED], [INFOTRIEVE]
- Pugliese A, Marinelli L, Forno B, Pollono A M, Uslenghi C, Girardello R. Ex vivo evaluation of Pidotimod effect on immune response. Pharmacol Res Sep., 1992; 26(Suppl 2)178–179, [PUBMED], [INFOTRIEVE]
- Benetti G P, Fugazza L, Stramba Badiale M, Montalto F, Bombelli G, La Vecchia G, Illeni M T, Uslenghi C. Ex vivo evaluation of Pidotimod activity on cell‐mediated immunity. Drug Res 1994; 44(II)1476
- Pidotimod. A new biological response modifier. Drug Res 1994; 44(II)1399–1530
- Nawrocki J, Kirstein E, Fisher R. Biochemical and structural properties of a Hodgkin's disease related membrane protein. J Immunol 1988; 141: 672–680, [PUBMED], [INFOTRIEVE]
- Del Prete G, De Carli M, Almerigogna F, Daniel C K, D'Elios M, Zancuoghi G, Vinante F, Pizzolo G, Romagnani S. Preferential expression of CD 30 by human CD4 + T cells producing Th2‐type cytokines. FASEB J 1995; 9(1)81–86, [PUBMED], [INFOTRIEVE], [CSA]
- Manetti R, Annunziato F, Biagiotti R, Giudizi M G, Piccinni M P, Giannarini L, Sampognaro S, Parronchi P, Vinante F, Pizzolo G. CD30 expression by CD8 + T cells clones in human immunodeficiency virus infection. J Exp Med 1994; 180(6)2407–2411, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Caproni M, Bianchi B, D'Elios A, Amedei M, Fabbri P. In vivo relevance of CD30 in atopic dermatitis. Allergy 1997; 52: 1063–1070, [PUBMED], [INFOTRIEVE], [CSA]
- Schandene L, Ferster A, Mascart‐Lemone F, Crusiaux A, Gerard C, Marchant A, Lybin M, Velu T, Sariban E, Goldman M. T helper type 2 like cells and therapeutic effects of interferon‐a in combined immunodeficiency and hypereosinophilia (Omenn's syndrome). Eur J Immunol 1993; 23(1)56–60, [PUBMED], [INFOTRIEVE], [CSA]
- Alzona M, Jack H M, Fisher R I, Ellis T M. CD30 defines a subset of activated human T cells that produce IFN‐gamma and IL‐5 and exhibit enchanced B cell helper activity. J Immunol 1994; 153(7)2861–2867, [PUBMED], [INFOTRIEVE]
- Hamann D, Hilkens C M, Grogan J L, Lens S M, Kapsenberg M L, Yazdanbakhsh M, Van Lier R A. CD30 expression does not discriminate between human Th1‐ and Th2‐type cells. J Immunol 1996; 156(4)1387–1391, [PUBMED], [INFOTRIEVE]